Germany · Delayed Price · Currency is EUR Transgene Company Description
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastrointestinal adenocarcinoma; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors.
The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, and BioInvent.
The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
| Country | France |
| Founded | 1979 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 144 |
| CEO | Alessandro Riva |
Contact Details
Address: 400, boulevard Gonthier d’Andernach Illkirch-Graffenstaden, 67405 France | |
| Phone | 33 3 88 27 91 00 |
| Website | transgene.fr |
Stock Details
| Ticker Symbol | TGNA |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Alessandro Riva | Chief Executive Officer |
| Lucie Larguier | Chief Financial Officer |